Sort
10,766 grants matching “checkpoint inhibitor”
Targeting a PHGDH metabolic vulnerability in melanoma
$433,256Florian Karreth · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2024 · CA
Role of histotripsy synergized CD40 signaling in the re-engineering of cold tumors
$433,173Ashish Ranjan · Oklahoma State University Stillwater · R01 · FY2022 · CA
Lung Cancer Vaccine
$433,048Nasser Khaled Altorki · Weill Medical Coll Of Cornell Univ · U54 · FY2025 · CA
Molecular Imaging and Metabolotheranostics of PDAC-Induced Cachexia
$432,889Zaver M Bhujwalla · Johns Hopkins University · R01 · FY2025 · CA
AUGMENTING ANTITUMOR T-CELL RECRUITMENT AND ACTIVATION IN LOCALIZED NSCLC TUMORS TO IMPROVE CHECKPOINT INHIBITOR THERAPY
$432,500Beckman Research Institute Of The City Of Hope · · FY2019 · Department of the Army
Targeting mechanisms of immune evasion in chemotherapy-induced senescent cells
$432,347James Jackson · Tulane University Of Louisiana · R01 · FY2022 · CA
Project 3: Demethylation of HPV-associated head and neck cancer to trigger APOBEC synthetic lethality and enhance immune response
$432,279Karen S Anderson · Yale University · P50 · FY2024 · DE
Understand & overcome resistance to PD-1
$432,274Paul Nghiem · University Of Washington · P01 · FY2025 · CA
Epigenetic Synergy Between DNMT and EZH1/2 Inhibitors for Therapy in Solid Tumors
$432,171Scott Rothbart · Coriell Institute For Medical Research · P50 · FY2021 · CA
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer
$432,128Kent W Mouw · Dana-Farber Cancer Inst · R01 · FY2022 · CA
RasGRP3 and Protein Kinase D as therapeutic targets for Uveal Melanoma
$432,122Xu Chen · University Of California, San Francisco · R01 · FY2024 · CA
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma
$431,993Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2025 · CA
Targeting LSD1 to prevent therapy-induced transdifferentiation in BRAF mutant colorectal cancer
$431,920Heather M O'Hagan · Indiana University Indianapolis · R01 · FY2024 · CA
Targeting immune suppressive microenvironment in ATC
$431,902James A Fagin · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Targeting immune suppressive microenvironment in ATC
$431,902James A Fagin · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
ALDH Inhibition as Modulator of Tumor Immunobiology
$431,843Ronald J Buckanovich · Magee-Women'S Res Inst And Foundation · R01 · FY2022 · CA
A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma
$431,749Frederick F Lang · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
RCAN 1.4 metastasis suppressor in thyroid cancer
$431,712Matthew D Ringel · Ohio State University · R01 · FY2024 · CA
A Mouse Model to Assess Long Term Immunotherapy-related Adverse Effects in Children
$431,631Pan Zheng · University Of Maryland Baltimore · R01 · FY2018 · CA
Targeting Gq pathway in uveal melanoma
$431,571Xu Chen · University Of California, San Francisco · R01 · FY2024 · CA
Targeting HMGA1 Tumor-Stromal Networks in Pancreatic Carcinogenesis
$431,561Linda M S Resar · Johns Hopkins University · R01 · FY2024 · CA
Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interface
$431,440Melody A Swartz · University Of Chicago · R01 · FY2023 · CA
Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interface
$431,440Melody A Swartz · University Of Chicago · R01 · FY2022 · CA
Immune activation by necroptotic cell death
$431,384Andrew Atwell Oberst · University Of Washington · R01 · FY2020 · CA
Augmenting Anti-Tumor Immunity Using Radiation in the Setting of DNA Repair Defects
$431,284Simona Shaitelman · University Of Tx Md Anderson Can Ctr · R21 · FY2020 · CA